Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Surely SDC 1801 has two major things going for it - low toxicity ( likely on current info) and the potential to be able to treat a range of auto immune indications and respiratory conditions - listed in the patents.
It would be to `Sareum’s advantage if possible to get further research on how wide the “range “ of indications might be ( Biomarkers? ) by the time the psoriasis phase 1 is completed at the end of this year. A likely best in class for psoriasis (indicated at the end of phase 1 and further evidence supporting potential multiple applicability would be a tough call for pharmas to ignore. OK it’s a big “if” but should it materialise then you can wave good bye to £3.00.
Celtic - this may help
https://www.icr.ac.uk/about-us/policy-and-engagement/use-of-biomarkers-in-cancer-research-and-treatment
Just noticed on the latest RNS that the Japanese patent application for SD -1801 has special status ( high priority). Applicants must create and submit a formal request asking that their patent application be examined before othe pending applications to receive this status. Common reasons to seek patent application special status include attracting investors.
Not sure if Sareum has this special status on the other worldwide patents for SDC 1801 or whether it is just for Japan. If so why?
Just looking at Takeda Pharmaceutical. A main area of focus for them is Gastrointestinal and inflammation. Quote “ understanding and addressing life limiting gastrointestinal and inflammatory diseases”.
The Japanese patent announced today ( and the Chinese patent announced earlier) cover the process for treating multi inflammatory and Autoimmune diseases. What’s not to like. Might the patent agreements in Asian give pharmas like Takeda an edge over European competitors at present?
Ahfam and if it goes to £2 are us long term holders going to sell? Probably not. So what’s the problem - the trials are progressing well as far as we know. Just sit tight. No problem for me as I have been invested for rather a long time and am staying until the endgame. It’s all or nothing.
TYK2 is hot and SD 1801 may be able to deal with a number of autoimmune ailments as well as respiratory. You don’ t risk spending around 5 Billion before thoroughly checking its potential. We just need to be patient a little longer (easy considering how many here have been invested for a number of years). This coming new year is going to be a bit special.
25 Mar 2021 14:07
RNS Number : 5356T
Sareum Holdings PLC
25 March 2021
SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Sareum Notes SRA737 Combination Data to be Presented at the AACR Annual Meeting
Cambridge, UK, 25 March 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, notes that researchers from the Institute of Cancer Research (ICR) will present preclinical data on the combination of the Chk1 inhibitor SRA737 with AstraZeneca's WEE1 inhibitor, adavosertib, at the forthcoming American Association for Cancer Research (AACR) Annual Meeting.
SRA737 was discovered and initially developed by scientists at The ICR in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology, in a c.$300 million plus royalties licence deal, with Sareum eligible to receive 27.5% of all payments to CPF under the agreement.
The poster* describes how the combination of SRA737 and adavosertib potentiated cell death in cellular models of ovarian, breast and pancreatic cancer and in disease model studies of ovarian and breast cancer.
* "A study of combinatorial growth inhibition, cell death and DNA damage repair caused by CHK1 inhibitor SRA737 and WEE1 inhibitor adavosertib in TP53 mutated cell lines" (Abstract 1010), to be presented on-line during the "Cellular Responses to Anticancer Drugs" session on 10 April 2021. https://www.abstractsonline.com/pp8/#!/9325/presentation/2082
Sareum's CSO, Dr John Reader, commented: "We are encouraged to see yet another potential treatment modality for SRA737, in this case in tumours with a TP53 mutation, a mutation that is present in approximately half of all solid tumour cancers."
Https://www.icr.ac.uk/news-archive/icr-and-merck-renew-strategic-alliance-in-discovery-and-development-of-innovative-new-small-molecule-cancer-drugs
A but more detail
Can anyone explain why the share price is going down around 1.3% daily when in most cases recently there has been more blue than red, including today. How does the Potential £5 million loan deal affect the trading given the trades we see have been more often blue. Could it possibly be market manipulation by MMS or is it something more fundamental connected with the loan deal. If anyone could explain that would be appreciated.
Sareum’s website of potential indications for SDC-1801 are:-
Psoriasis. Market valuation of 55.7 Billion Dollars by 2032
Rheumatoid Arthritis - 34.47 dollars in 2022
Lupus. - 3,517 million dollars growing 7% 2022-2030
Inflammatory bowel Disease 20.33 billion dollars in 2022
Multiple sclerosis 31.90 billion dollars by 2030
Severe respiratory disease 14 billion dollars in 2022 with annual growth 6.5%
And there could be many more indications ( over 30 in the patent applications.
All we need to do is ace the trials. Exciting.
Https://www.insidermedia.com/news/north-west/genedrive-secures-new-funding-facility
Note the similarity to Sareum’s Facility. Peel Hunt involved in both.